EDAP TMS S.A. Reports 38.8% Revenue Growth in Q2 2026 Despite Increased Net Loss

EDAP TMS S.A. reported significant financial results for the second quarter of 2026, with total revenues reaching $13.2 million, a 38.8% increase from $9.5 million in the same period of 2025. For the first half of 2026, revenues totaled $24.8 million, up 54.9% from $16.0 million year-over-year. The growth was primarily driven by a 57.5% increase in medical device sales, which amounted to $7.5 million, and a 37.5% rise in treatment-driven revenue, totaling $5.0 million. Despite this revenue growth, the company reported a net loss of $14.5 million for the quarter, compared to a loss of $6.4 million in Q2 2025, and a net loss of $23.6 million for the first half of 2026, up from $13.9 million in the prior year.

The company has undergone a strategic shift, announcing on May 28, 2026, its decision to exit the Extracorporeal Shock Wave Lithotripsy (ESWL) and Distribution segments to focus exclusively on its High Intensity Focused Ultrasound (HIFU) business. This decision was made to concentrate resources on the Focal One® HIFU platform, which is expected to enhance operational efficiency and financial performance. The ESWL and Distribution segments have been classified as discontinued operations, and their results are excluded from the continuing operations reported in the financial statements.

Operationally, EDAP TMS S.A. sold 13 Focal One units in the second quarter of 2026, compared to 9 units in the same quarter of 2025. The company’s gross profit margin improved to 55.6% in Q2 2026, up from 51.1% in Q2 2025, attributed to better cost management and increased production volumes. However, total operating expenses rose to $15.4 million in Q2 2026, a 33.8% increase from $11.5 million in the same quarter of 2025, driven by higher marketing and administrative costs associated with the transition to a domestic filer status.

As of June 30, 2026, EDAP TMS S.A. reported total assets of $74.5 million, a decrease from $79.0 million at the end of 2025. The company’s cash and cash equivalents increased to $21.5 million, up from $20.5 million at the end of the previous year. The company also completed a public offering of American Depositary Shares (ADSs) in August 2026, raising approximately $37.1 million in net proceeds, which is expected to support ongoing operations and capital expenditures.

Looking ahead, EDAP TMS S.A. anticipates continued losses as it focuses on the growth of its HIFU business. The company aims to leverage the recent capital influx to enhance its sales and marketing efforts and expand research and development initiatives. The successful commercialization and adoption of its products will be critical to achieving profitability in the future. The company remains committed to managing its operating expenses and navigating market conditions to improve its financial performance.